论文部分内容阅读
为探讨癌基因突变、扩增与非小细胞肺癌发生及类型间的关系，应用核酸杂交的方法检测了63伤1肺手术标本中（腺癌19例，鳞癌23例，腺鳞癌3例，大细胞癌3例，小细胞癌3例，其它12例）三种癌基因（c－myc、K－ras、erbB－2）的扩增及突变。实验结果显示：50％（24／48）的非小细胞癌分别出现三种癌基因的激活；31．6％（6／19）的腺癌出现K－ras12密码子突变及K－ras扩增；30．4％（7／23）的鳞癌有erbB－2扩增；10．4％（5／48）的非小细胞癌存在c－myc扩增。提示K－ras突变可能为肺腺癌所特有，而erbB－2扩增是肺鳞癌发生的重要因素。
To investigate the relationship between oncogene mutations, amplification and the occurrence and types of non-small cell lung cancer, 63 invasive lung surgical specimens (adenocarcinoma 19 cases, squamous cell carcinoma 23 cases, adenosquamous carcinoma 3 cases) were detected by nucleic acid hybridization. There were 3 large cell carcinomas, 3 small cell carcinomas, and 12 other cases) amplification and mutation of three oncogenes (c-myc, K-ras, erbB-2). The experimental results showed that 50% (24/48) of non-small cell carcinomas were activated by three oncogenes respectively; 31.6% (6/19) of adenocarcinomas showed K-ras12 codon mutations and K-ras amplification. 30.4% (7/23) of squamous cell carcinomas had erbB-2 amplification; 10.4% (5/48) of non-small cell carcinomas had c-myc amplification. The K-ras mutation may be unique to lung adenocarcinoma, and erbB-2 amplification is an important factor in the development of lung squamous cell carcinoma.